美国生物制药企业亚力兄制药宣布,其核心产品SYFOVRE®(佩西他普兰注射液)的五项研究摘要获选美国视网膜专家协会(ASRS)年度科学会议口头报告。会议将于7月30日至8月2日在加州长滩举行,最新数据将重点展示该药物对年龄相关性黄斑变性(AMD)继发地理萎缩(GA)患者的疗效与安全性。
本次披露的研究数据涵盖三大关键维度:地理萎缩进展相关的基线特征、早期干预与延迟治疗的效果对比、以及双眼GA病例中健眼数据的临床应用价值。视网膜领域权威专家还将同步呈现两项专项分析——包括佩西他普兰与抗血管内皮生长因子联合治疗患者的描述性研究,以及AREDS口服微量营养素补充剂对疗效的影响评估。
值得关注的是,针对治疗时机的对比研究首次揭示早期介入组相较延迟治疗组呈现更优的病灶控制效果。在涉及双侧病变的前瞻性分析中,健眼数据被证实可作为疾病进展的重要预测指标,为临床诊疗提供新思路。
(注:本文内容基于企业公告信息编制,不构成任何投资建议)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.